Diversity covering AMA1-MSP119fusion proteins as malaria vaccines

Infection and Immunity

Volumn 81, Issue 5, 2013, Pages 1479-1490

  Faber, Bart W ^a   Younis, Sumera ^a   Remarque, Edmond J ^a   Garcia, Roberto Rodriguez ^a   Riasat, Vanessa ^a   Walraven, Vanessa ^a   van der Werff, Nicole ^a   van der Eijk, Marjolein ^a   Cavanagh, David R ^b   Holder, Anthony A ^c   Thomas, Alan W ^a   Kocken, Clemens H M ^a  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APICAL MEMBRANE ANTIGEN 1 MEROZOITE SURFACE PROTEIN 1 VACCINE; MALARIA VACCINE; UNCLASSIFIED DRUG;

ALLELE; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIMALARIAL ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; GROWTH INHIBITION; IC 50; IMMUNIZATION; MALARIA FALCIPARUM; MICROBIAL DIVERSITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; DISEASE MODELS, ANIMAL; MALARIA VACCINES; MEMBRANE PROTEINS; MEROZOITE SURFACE PROTEIN 1; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; RABBITS;

EID: 84877837444     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01267-12     Document Type: Article

References (51)

1. Mendis K, Rietveld A, Warsame M, Bosman A, Greenwood B, Wernsdorfer WH. 2009. From malaria control to eradication: the WHO perspective. Trop. Med. Int. Health 14:802-809.
2. World Health Organization. 2010. World malaria report: 2010. World Health Organization, Geneva, Switzerland.
3. Murray CJ, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, Fullman N, Naghavi M, Lozano R, Lopez AD. 2012. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 379:413-431.
4. Bhattarai A, Ali AS, Kachur SP, Martensson A, Abbas AK, Khatib R, Al-Mafazy AW, Ramsan M, Rotllant G, Gerstenmaier JF, Molteni F, Abdulla S, Montgomery SM, Kaneko A, Bjorkman A. 2007. Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. PLoS Med. 4:e309. doi:10.1371/journal .pmed.0040309.
5. Gordon DM, McGovern TW, Krzych U, Cohen JC, Schneider I, La- Chance R, Heppner DG, Yuan G, Hollingdale M, Slaoui M, Hauser P, Voet P, Sadoff JC, Ballou WR. 1995. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J. Infect. Dis. 171:1576-1585.
6. Mueller AK, Labaied M, Kappe SH, Matuschewski K. 2005. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 433:164-167.
7. Hoffman SL, Billingsley PF, James E, Richman A, Loyevsky M, Li T, Chakravarty S, Gunasekera A, Li M, Stafford R, Ahumada A, Epstein JE, Sedegah M, Reyes S, Richie TL, Lyke KE, Edelman R, Laurens M, Plowe CV, Sim BK. 2010. Development of a metabolically active, nonreplicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum. Vaccin. 6:97-106.
8. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, Methogo BG, Doucka Y, Flamen A, Mordmuller B, Issifou S, Kremsner PG, Sacarlal J, Aide P, Lanaspa M, Aponte JJ, Nhamuave A, Quelhas D, Bassat Q, Mandjate S, Macete E, Alonso P, Abdulla S, Salim N, Juma O, Shomari M, Shubis K, Machera F, Hamad AS, Minja R, Mtoro A, Sykes A, Ahmed S, Urassa AM, Ali AM, Mwangoka G, Tanner M, Tinto H, D'Alessandro U, Sorgho H, Valea I, Tahita MC, Kabore W, Ouedraogo S, Sandrine Y, Guiguemde RT, Ouedraogo JB, Hamel MJ, Kariuki S, Odero C, et al. 2011. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N. Engl. J. Med. 365:1863-1875.
9. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, Aide P, Sigauque B, Milman J, Mandomando I, Bassat Q, Guinovart C, Espasa M, Corachan S, Lievens M, Navia MM, Dubois MC, Menendez C, Dubovsky F, Cohen J, Thompson R, Ballou WR. 2005. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 366:2012-2018.
10. Scheller LF, Azad AF. 1995. Maintenance of protective immunity against malaria by persistent hepatic parasites derived from irradiated sporozoites. Proc. Natl. Acad. Sci. U. S. A. 92:4066-4068.
11. Bejon P, Cook J, Bergmann-Leitner E, Olotu A, Lusingu J, Mwacharo J, Vekemans J, Njuguna P, Leach A, Lievens M, Dutta S, von Seidlein L, Savarese B, Villafana T, Lemnge MM, Cohen J, Marsh K, Corran PH, Angov E, Riley EM, Drakeley CJ. 2011. Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children. J. Infect. Dis. 204:9-18.
12. Douglas AD, Williams AR, Illingworth JJ, Kamuyu G, Biswas S, Goodman AL, Wyllie DH, Crosnier C, Miura K, Wright GJ, Long CA, Osier FH, Marsh K, Turner AV, Hill AV, Draper SJ. 2011. The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody. Nat. Commun. 2:601. doi:10.1038/ncomms1615.
13. Triglia T, Healer J, Caruana SR, Hodder AN, Anders RF, Crabb BS, Cowman AF. 2000. Apical membrane antigen 1 plays a central role in erythrocyte invasion by Plasmodium species. Mol. Microbiol. 38:706-718.
14. Sanders PR, Kats LM, Drew DR, O'Donnell RA, O'Neill M, Maier AG, Coppel RL, Crabb BS. 2006. A set of glycosylphosphatidyl inositolanchored membrane proteins of Plasmodium falciparum is refractory to genetic deletion. Infect. Immun. 74:4330-4338.
15. Silvie O, Franetich JF, Charrin S, Mueller MS, Siau A, Bodescot M, Rubinstein E, Hannoun L, Charoenvit Y, Kocken CH, Thomas AW, Van Gemert GJ, Sauerwein RW, Blackman MJ, Anders RF, Pluschke G, Mazier D. 2004. A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. J. Biol. Chem. 279: 9490-9496.
16. Lasonder E, Ishihama Y, Andersen JS, Vermunt AM, Pain A, Sauerwein RW, Eling WM, Hall N, Waters AP, Stunnenberg HG, Mann M. 2002. Analysis of the Plasmodium falciparum proteome by high-accuracy mass spectrometry. Nature 419:537-542.
17. Bozdech Z, Llinas M, Pulliam BL, Wong ED, Zhu J, DeRisi JL. 2003. The transcriptome of the intraerythrocytic developmental cycle of Plasmodium falciparum. PLoS Biol. 1:E5. doi:10.1371/journal.pbio.0000005.
18. Szarfman A, Walliker D, McBride JS, Lyon JA, Quakyi IA, Carter R. 1988. Allelic forms of gp195, a major blood-stage antigen of Plasmodium falciparum, are expressed in liver stages. J. Exp. Med. 167:231-236.
19. Remarque EJ, Faber BW, Kocken CH, Thomas AW. 2008. Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol. 24:74-84.
20. Holder AA. 2009. The carboxy-terminus of merozoite surface protein 1: structure, specific antibodies and immunity to malaria. Parasitology 136: 1445-1456.
21. Mahdi Abdel Hamid M, Remarque EJ, van Duivenvoorde LM, van der Werff N, Walraven V, Faber BW, Kocken CH, Thomas AW. 2011. Vaccination with Plasmodium knowlesi AMA1 formulated in the novel adjuvant co-vaccine HT protects against blood-stage challenge in rhesus macaques. PLoS One 6:e20547. doi:10.1371/journal.pone.0020547.
22. Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Ouattara A, Kone AK, Guindo AB, Traore K, Traore I, Kouriba B, Diallo DA, Diarra I, Daou M, Dolo A, Tolo Y, Sissoko MS, Niangaly A, Sissoko M, Takala- Harrison S, Lyke KE, Wu Y, Blackwelder WC, Godeaux O, Vekemans J, Dubois MC, Ballou WR, Cohen J, Thompson D, Dube T, Soisson L, Diggs CL, House B, Lanar DE, Dutta S, Heppner DG, Jr, Plowe CV. 2011. A field trial to assess a blood-stage malaria vaccine. N. Engl. J. Med. 365:1004-1013.
23. Tanabe K, Mackay M, Goman M, Scaife JG. 1987. Allelic dimorphism in a surface antigen gene of the malaria parasite Plasmodium falciparum. J. Mol. Biol. 195:273-287.
24. Takala SL, Plowe CV. 2009. Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria'. Parasite Immunol. 31:560-573. 25. Remarque EJ, Faber BW, Kocken CH, Thomas AW. 2008. A diversitycovering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits. Infect. Immun. 76:2660-2670.
25. Remarque EJ, Faber BW, Kocken CH, Thomas AW. 2008. A diversitycovering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits. Infect. Immun. 76:2660-2670.
26. Chesne-Seck ML, Pizarro JC, Normand BV, Collins CR, Blackman MJ, Faber BW, Remarque EJ, Kocken CH, Thomas AW, Bentley GA. 2005. Structural comparison of apical membrane antigen 1 orthologues and paralogues in apicomplexan parasites. Mol. Biochem. Parasitol. 144:55-67.
27. Bai T, Becker M, Gupta A, Strike P, Murphy VJ, Anders RF, Batchelor AH. 2005. Structure of AMA1 from Plasmodium falciparum reveals a clustering of polymorphisms that surround a conserved hydrophobic pocket. Proc. Natl. Acad. Sci. U. S. A. 102:12736-12741.
28. Ellis RD, Wu Y, Martin LB, Shaffer D, Miura K, Aebig J, Orcutt A, Rausch K, Zhu D, Mogensen A, Fay MP, Narum DL, Long C, Miller L, Durbin AP. 2012. Phase 1 study in malaria naive adults of BSAM2/ Alhydrogel(R)CPG 7909, a blood stage vaccine against P. falciparum malaria. PLoS One 7:e46094. doi:10.1371/journal.pone.0046094.
29. Faber BW, Remarque EJ, Morgan WD, Kocken CH, Holder AA,Thomas AW. 2007. Malaria vaccine-related benefits of a single protein comprising Plasmodium falciparum apical membrane antigen 1 domains I and II fused to a modified form of the 19-kilodalton C-terminal fragment of merozoite surface protein 1. Infect. Immun. 75:5947-5955.
30. Hensmann M, Li C, Moss C, Lindo V, Greer F, Watts C, Ogun SA, Holder AA, Langhorne J. 2004. Disulfide bonds in merozoite surface protein 1 of the malaria parasite impede efficient antigen processing and affect the in vivo antibody response. Eur. J. Immunol. 34:639-648.
31. Morgan WD, Birdsall B, Frenkiel TA, Gradwell MG, Burghaus PA, Syed SE, Uthaipibull C, Holder AA, Feeney J. 1999. Solution structure of an EGF module pair from the Plasmodium falciparum merozoite surface protein 1. J. Mol. Biol. 289:113-122.
32. Kennedy MC, Wang J, Zhang Y, Miles AP, Chitsaz F, Saul A, Long CA, Miller LH, Stowers AW. 2002. In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect. Immun. 70:6948-6960.
33. Faber BW, Remarque EJ, Kocken CH, Cheront P, Cingolani D, Xhonneux F, Jurado M, Haumont M, Jepsen S, Leroy O, Thomas AW. 2008. Production, quality control, stability and pharmacotoxicity of cGMPproduced Plasmodium falciparum AMA1 FVO strain ectodomain expressed in Pichia pastoris. Vaccine 26:6143-6150.
34. Kusi KA, Faber BW, Thomas AW, Remarque EJ. 2009. Humoral immune response to mixed PfAMA1 alleles; multivalent PfAMA1 vaccines induce broad specificity. PLoS One 4:e8110. doi:10.1371/journal.pone .0008110.
35. Kocken CH, van der Wel AM, Dubbeld MA, Narum DL, van de Rijke FM, van Gemert GJ, van der Linde X, Bannister LH, Janse C, Waters AP, Thomas AW. 1998. Precise timing of expression of a Plasmodium falciparum-derived transgene in Plasmodium berghei is a critical determinant of subsequent subcellular localization. J. Biol. Chem. 273:15119-15124.
36. Narum DL, Thomas AW. 1994. Differential localization of full-length and processed forms of PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum merozoites. Mol. Biochem. Parasitol. 67:59-68.
37. McBride JS, Heidrich HG. 1987. Fragments of the polymorphic Mr 185,000 glycoprotein from the surface of isolated Plasmodium falciparum merozoites form an antigenic complex. Mol. Biochem. Parasitol. 23:71-84.
38. Hilgers LA, Blom AG. 2006. Sucrose fatty acid sulphate esters as novel vaccine adjuvant. Vaccine 24(Suppl 2):S2-81-S2-82.
39. Remarque EJ, Roestenberg M, Younis S, Walraven V, van der Werff N, Faber BW, Leroy O, Sauerwein R, Kocken CH, Thomas AW. 2012. Humoral immune responses to a single allele PfAMA1 vaccine in healthy malaria-naive adults. PLoS One 7:e38898. doi:10.1371/journal.pone .0038898.
40. Martens S, Borchert S-O, Faber BW, Cornelissen G, Luttmann R. 2011. Fully automated production of potential malaria vaccines with Pichia pastoris in integrated processing. Eng. Life Sci. 11:429-435.
41. Tsai CW, Duggan PF, Shimp RL, Jr, Miller LH, Narum DL. 2006. Overproduction of Pichia pastoris or Plasmodium falciparum protein disulfide isomerase affects expression, folding and O-linked glycosylation of a malaria vaccine candidate expressed in P. pastoris. J. Biotechnol. 121: 458-470.
42. Roestenberg M, Remarque E, de Jonge E, Hermsen R, Blythman H, Leroy O, Imoukhuede E, Jepsen S, Ofori-Anyinam O, Faber B, Kocken CH, Arnold M, Walraven V, Teelen K, Roeffen W, de Mast Q, Ballou WR, Cohen J, Dubois MC, Ascarateil S, van der Ven A, Thomas A, Sauerwein R. 2008. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. PLoS One 3:e3960. doi:10.1371/journal.pone .0003960.
43. Howell SA, Withers-Martinez C, Kocken CH, Thomas AW, Blackman MJ. 2001. Proteolytic processing and primary structure of Plasmodium falciparum apical membrane antigen-1. J. Biol. Chem. 276:31311-31320.
44. Stanisic DI, Martin LB, Liu XQ, Jackson D, Cooper J, Good MF. 2003. Analysis of immunological nonresponsiveness to the 19-kilodalton fragment of merozoite surface protein 1 of Plasmodium yoelii: rescue by chemical conjugation to diphtheria toxoid (DT) and enhancement of immunogenicity by prior DT vaccination. Infect. Immun. 71:5700-5713.
45. Kusi KA, Faber BW, van der Eijk M, Thomas AW, Kocken CH, Remarque EJ. 2011. Immunization with different PfAMA1 alleles in sequence induces clonal imprint humoral responses that are similar to responses induced by the same alleles as a vaccine cocktail in rabbits. Malar. J. 10:40. doi:10.1186/1475-2875-10-40.
46. Kusi KA, Faber BW, Riasat V, Thomas AW, Kocken CH, Remarque EJ. 2010. Generation of humoral immune responses to multi-allele PfAMA1 vaccines; effect of adjuvant and number of component alleles on the breadth of response. PLoS One 5:e15391. doi:10.1371/journal.pone .0015391.
47. Corran PH, O'Donnell RA, Todd J, Uthaipibull C, Holder AA, Crabb BS, Riley EM. 2004. The fine specificity, but not the invasion inhibitory activity, of 19-kilodalton merozoite surface protein 1-specific antibodies is associated with resistance to malarial parasitemia in a cross-sectional survey in The Gambia. Infect. Immun. 72:6185-6189.
48. Ngoundou-Landji J, Nwuba RI, Anumudu CI, Odaibo AB, Matondo Maya WD, Awobode HO, Okafor CM, Morenikeji OA, Asinobi A, Nwagwu M, Holder AA, Ntoumi F. 2010. Fine specificity of anti-MSP119 antibodies and multiplicity of Plasmodium falciparum merozoite surface protein 1 types in individuals in Nigeria with sub-microscopic infection. Malar. J. 9:287. doi:10.1186/1475-2875-9-287.
49. Okech BA, Corran PH, Todd J, Joynson-Hicks A, Uthaipibull C, Egwang TG, Holder AA, Riley EM. 2004. Fine specificity of serum antibodies to Plasmodium falciparum merozoite surface protein, PfMSP-1(19), predicts protection from malaria infection and high-density parasitemia. Infect. Immun. 72:1557-1567.
50. Arnot DE, Cavanagh DR, Remarque EJ, Creasey AM, Sowa MP, Morgan WD, Holder AA, Longacre S, Thomas AW. 2008. Comparative testing of six antigen-based malaria vaccine candidates directed toward merozoite-stage Plasmodium falciparum. Clin. Vaccine Immunol. 15: 1345-1355.
51. McIntosh RS, Shi J, Jennings RM, Chappel JC, de Koning-Ward TF, Smith T, Green J, van Egmond M, Leusen JH, Lazarou M, van de Winkel J, Jones TS, Crabb BS, Holder AA, Pleass RJ. 2007. The importance of human FcgammaRI in mediating protection to malaria. PLoS Pathog. 3:e72. doi:10.1371/journal.ppat.0030072.